source
- Encoded Therapeutics secures $275M Series F to advance gene therapy for Dravet syndromeEncoded Therapeutics announced a $275 million Series F financing round aimed at moving its lead gene‑therapy candidate, ETX101, toward pivotal trials for Dravet syndrome. In the ongoing Phase 1/2…
- FDA signals openness to innovative trial designs for psychedelic therapiesFDA regulators said they are willing to consider more flexible approaches for evaluating psychedelic medicines. The agency noted that studies could use active comparators instead of placebo, which…